Functional outcome in schizophrenia: A comparative cross-sectional study on first versus second generation antipsychotics;Esito funzionale nella schizofrenia: Uno studio trasversale di confronto tra antipsicotici di prima e di seconda generazione

Rivista di Psichiatria

Volumn 44, Issue 2, 2009, Pages 110-116

  Montemagni, Cristiana ^a   Birindelli, Nadia ^a   Castagna, Filomena ^a   Mingrone, Cinzia ^a   Sigaudo, Monica ^a   Zappia, Serena ^a   Rocca, Paola ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Executive functions; First generation antipsychotics; Quality of life; Schizophrenia; Second generation antipsychotics; Social functioning

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FUNCTIONAL ASSESSMENT; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; JOB ADAPTATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL INTERACTION; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; WISCONSIN CARD SORTING TEST;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 67549084767     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Mueser KT (Sharma T, Harvey P eds): Cognition in schizophrenia. Oxford University Press, New York, 2000.
2. Hofer A, Baumgartner S, Bodner T, Edlinger M, Hummer M, Kemmler G, et al.: Patient outcomes in schizophrenia II: the impact of cognition. European Psychiatry, 2005,20,395-402.
3. Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE: Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophrenia Bulletin, 2005,31,167-74.
4. Milev P, Ho BC, Arndt S, Andreasen NC: Predictive values of neurocognition and negative symptoms on functional outcome
5. Green MF: What are the functional consequences of neurocog- nitive deficits in schizophrenia? American Journal of Psychiatry, 1996,153,321-333.
6. Bowie CR, Harvey PD: Cognition in schizophrenia: impairments, determinants, and functional importance. The Psychiatric Clinics of North America, 2005,28,613-633.
7. Meltzer HY, McGurk SR: The effect of clozapine, olanzapine and risperidone on cognitive function in schizophrenia. Schizophrenia Bulletin, 1999, 25,233-255.
8. ;
9. Beasley CM.Tollefson G,Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North-American double-blind olanzapine trial. Neuropsychopharmacplogy, 1996,14,111-123.
10. Leucht S, Pitschel-Walz G, Engel RR, Kissling W: Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. American Journal of Psychiatry, 2002,159, 180-190.
11. :The effects of atypical antipsychotics drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin, 1999,25,201-222.
12. Fujii DE, Wylie AM: Neurocognition and community outcome in schizophrenia: long-term predictive validity. Schizophrenia Research, 2003,59,219-223.
13. Muller U, Werheid K, Hammerstein E, Jungmann S, Becker T: Prefrontal cognitive deficits in patients with schizophrenia treated with atypical or conventional antipsychotics. European Psychiatry, 2005,20,70-73.
14. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A: One year double-blind study of the neurocognitive efficacy of olanzapine, risperidone and haloperidol in schizophrenia. Schizophrenia Research, 2006,81,1-15.
15. Bender S, Dittmann-Balcar A, Schall U, Wolstein J, Klimke A, Riedel M, et al.: Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. International Journal of Neuropharmacology, 2006,9,135-145.
16. Green MF, Satz P, Ganzell S, Vavlav JF: Wisconsin Card Sorting Test performance in schizophrenia: remediation of a stubborn deficit. American Journal of Psychiatry, 2002,149,62-67.
17. Saleem P, Oliè JP, Loo H: Social functioning and quality of life in the schizophrenic patient. Advantages of amisulpride. International Clinical Psychopharmacology, 2002,17,1-8.
18. Priebe S: Social outcomes in schizophrenia. British Journal of Psychiatry, 2007,191, S15-20.
19. Watts J, Priebe S: A phenomenological account of users' experiences of assertive community treatment. Bioethics, 2002,16,439- 454.
20. Bobes J, García-Portilla MP, Bascaran MT, Saiz PA, Bousoño M: Quality of life in schizophrenic patients. Dialogues of Clinical Neuroscience, 2007,9,215-226.
21. Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W, Schimmelmann BG, et al.: Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Journal of Psychiatry Research, 2008, 42, 676-683.
22. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research, 2000,43,135-145.
23. Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y: Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. Journal of Clinical Psychopharmacology, 2004,24,582-591.
24. Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green Al, Tohen M, et al.: Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophrenia Research, 2005,78,161-169.
25. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, et al.: Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. Journal of Clinical Psychiatry, 2006,67,1690-1697.
26. nd edition). Oxford University Press, NewYork, 1996.
27. Bowie CR, Leung WW, Reichenberg A, McClure M, Patterson TL, Heaton RK, et al.: Predicting schizophrenia patients' real- world behaviour with specific neuropsychological and functional capacity measures. Biological Psychiatry, 2008,63,505-511.
28. Berg EA: A simple objective treatment for measuring flexibility in thinkingi The Journal of General Psychology, 1948,39,15-22.
29. Grant DA, Berg E A: A behavioural analysis of the degree of reinforcement and ease of shifting to new responses in a Weigl- type card sorting problem. Journal of Experimental Psychology, 1948,38,404-411.
30. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G: Wisconsin Card Sorting Test manual revised and expanded. Psychological Assessment Resources, Inc. Florida, 1993.
31. Endicott J, Spitzer RL, Fleiss JL, Cohen J: The Global assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 1976, 33, 766.
32. Heinrichs DW, Hanion TE, Carpenter WT: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 1984,10,388-98.
33. Bobes J, Garcia-Portilla P, Saiz PA, Bascaran T, Bousono M: Quality of life measures in schizophrenia. European Psychiatry, 2005,20, S313-317.
34. Harvey PD, Velligan DI, Bellack AS: Performance-based measures of functional skills: usefulness in clinical treatment studies. Schizophrenia Bulletin, 2007,33,1138-1148.
35. Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry, 2003, 64, 663-667.
36. First MB, Gibbon M, Spitzer RL: Structured Clinical Interview for DSM-IV Disorder's (SCID). American Psychiatric Press, Washington DC, 1997.
37. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrom Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 1987,13,261-276.
38. Guy W: ECDEU assessment manual for psychopharmacology-revised. US Departement of Health, Education and Welfare, Bethesda (MD), 1976.
39. Addington D, Addington J, Schissel B: A depression rating scale for schizophrenics. Schizophrenia Research, 1990,3,247-251.
40. Martícnez-Arán A, Vieta E, Torrent C, Sánchez-Moreno J, Goikolea JM, Salamero M, et al.: Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disorders, 2007,9,103-113.
41. Tabarés-Seisdedos RT, Balanzá-Martínez V, Sánchez-Moreno J, Martínez-Arán A, Salazar-Fraile J, Selva-Vera J, et al.: Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. Journal of Affective Disorders, 2008,109,286- 299.
42. Rossi A, Daneluzzo E, Tomassini A, Struglia F, Cavajlaro R, Smeraldi E, et al.: The effect of verbalization strategy on Wisconsin test performance in schizophrenic patients receiving classical or atypical antipsychotics. BMC Psychiatry, 2006,6,1-6.
43. Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B: A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. Journal of Clinical Psychiatry, 2007,68,368-379.
44. Corrigan PW, Reinke RR, Landsberger SA, Charate A, Toombs GA: The effect of atypical antipsychotics on psychosocial outcomes. Schizophrenia Research, 2007,63,97-101.
45. Burns T, Patrick D: Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatrica Scandinavica,2007,116, 403-418.
46. Green MF: Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. American Journal of Psychiatry, 2007,164,992-994.